MBA, VP, BioPharma Business Development, Guardant Health, Inc.
Daniel is responsible for building Guardant’s partnerships with pharmaceutical and biotechnology companies using the Digital Sequencing technology platform. Daniel brings more than a decade of experience in the life sciences industry across business development, strategy, and operations. Previously, Daniel served in roles at MyoKardia, Onyx Pharmaceuticals, McKinsey & Company, and Genentech. He holds an MBA from the University of Pennsylvania’s Wharton School and an MA Hons. in Natural Sciences from the University of Cambridge.
Presentation Title and Company Description
Liquid Biopsy Showcase: Accelerating Clinical Trials with Comprehensive Liquid Biopsy
Using both molecular and digital tools, Guardant Health is addressing challenges across the cancer care continuum. Its first product, the Guardant360® assay, came to market in 2014, and is now the most widely ordered comprehensive liquid biopsy commercially available.